Given that America continues making unprecedented changes to its vaccination schedules, an unexpected name appears unexpectedly: Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning Covid vaccines in the pandemic and has focused upon potential deaths following Covid vaccination in her short time at the Food and Drug Administration.
Health officials had intended to reveal major revisions to the childhood immunization program recently, aligning the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US out of step with a large portion of the international standard with little proof for benefit. The planned update has been delayed until the coming year.
Rather than Vinay Prasad, Tracy Beth Høeg is listed to present at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this calendar year.
This interim role might represent a strengthened alliance between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back already-approved immunizations at the FDA.
Dr. Høeg has often pushed for discontinuing certain childhood immunization guidelines in the US in order to be more in line with Denmark, a country with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.
To date statements, she has persisted in emphasizing on vaccines – typically the purview of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.
The appointee has no obvious background in medication creation, oversight or management, which has been standard for past leaders of the CBER. She has been employed at the FDA as a key advisor to the commissioner and CBER since earlier this year.
“She appears not to have the requisite experience” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”
Former directors of CBER would “be deeply familiar with legal statutes and the science of medication creation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that prior appointees who headed the center have had.”
CDER has an vast portfolio at the agency, the former commissioner pointed out.
“Many people just focuses on the new drug program, but the generic drug division authorizes thousands of generic medications. There is also a biosimilars program, over-the-counter program and other areas, and each of these must be looked after,” she explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”
Additionally, a substantial administrative aspect to the job, which oversees over 5,000 personnel. “It is a massive management job, if you execute it properly,” Woodcock concluded.
Regarding inquiries about Dr. Høeg's credentials and whether this selection indicates increased cooperation among FDA leaders on vaccines, a press secretary stated that the “questions are based on flawed premises”.
“Her experience matches the functions of her position,” the official stated, citing the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computerized risk analysis and immunization monitoring”.
In her interim role, Dr. Høeg inherits the agency head's controversial expedited review system, a contentious rapid medication authorization process that apparently worried her predecessors. “How are these therapies being chosen for this expedited pathway? Who makes the calls?” Howard said. “There is a lot of confidentiality happening at the regulatory body right now.”
Broadly speaking, he said, “the FDA seems to be moving towards laxer regulations of pharmaceuticals, except for immunizations.”
Regarding vaccines, Dr. Høeg has a clearer, if problematic, history, some experts said. She released a research paper using unverified crowd-sourced reports to determine the incidence of myocarditis following Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are riskier than they are.
Among her “wish list” for the current administration encompassed changing guidelines for recently developed shots and halting “unnecessary” immunizations, she remarked post-election on a podcast. At the FDA, Høeg has allegedly suggested barring young men from getting COVID-19 vaccinations.
“She is an complete true believer who commences with her preconceived notions and reverse-engineers to fit the science in a highly misleading, untruthful fashion,” Dr. Howard said.
Høeg joined fellow dissenters, {like|
A seasoned casino analyst with over a decade of experience in gaming strategies and industry trends.
